{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05277051",
            "orgStudyIdInfo": {
                "id": "217228"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-004968-95",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "GlaxoSmithKline",
                "class": "INDUSTRY"
            },
            "briefTitle": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "first-time-in-human-study-of-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10-14",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10-14",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-03",
            "studyFirstSubmitQcDate": "2022-03-03",
            "studyFirstPostDateStruct": {
                "date": "2022-03-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GlaxoSmithKline",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted."
        },
        "conditionsModule": {
            "conditions": [
                "Neoplasms"
            ],
            "keywords": [
                "Advanced solid tumors",
                "Metastatic solid tumor",
                "Anticancer agents",
                "Dostarlimab",
                "GSK4381562",
                "GSK4428859A",
                "Head and neck squamous cell carcinoma (HNSCC)",
                "Non-small-cell lung cancer (NSCLC)",
                "Breast cancer (BC)",
                "Clear cell renal cell cancer (ccRCC)",
                "Gastric cancer (GC)",
                "Colorectal cancer (CRC)",
                "Endometrial cancer (EC)",
                "Ovarian epithelial cancer (OEC)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "3 Dose Escalation arms (Arm A: GSK4381562 alone; Arm B: GSK4381562 plus dostarlimab; Arm C: GSK4381562 plus dostarlimab plus GSK4428859A) and 1 new arm, Arm D (dostarlimab plus GSK4428859A). Additional participants may be enrolled in any study arms A, B or C in PK/Pharmacodynamic (PD) cohorts at putative recommended Phase 2 dose (RP2D) level and/or at previously cleared dose levels (up to 15 participants).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 162,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants receiving GSK4381562 monotherapy (Arm A)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK4381562"
                    ]
                },
                {
                    "label": "Participants receiving GSK4381562 plus dostarlimab (Arm B)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK4381562",
                        "Drug: Dostarlimab"
                    ]
                },
                {
                    "label": "Participants receiving GSK4381562 plus dostarlimab plus GSK4428859A (Arm C)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK4381562",
                        "Drug: Dostarlimab",
                        "Drug: GSK4428859A"
                    ]
                },
                {
                    "label": "Participants receiving dostarlimab plus GSK4428859A (Arm D)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Dostarlimab",
                        "Drug: GSK4428859A"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GSK4381562",
                    "description": "GSK4381562 will be administered.",
                    "armGroupLabels": [
                        "Participants receiving GSK4381562 monotherapy (Arm A)",
                        "Participants receiving GSK4381562 plus dostarlimab (Arm B)",
                        "Participants receiving GSK4381562 plus dostarlimab plus GSK4428859A (Arm C)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Dostarlimab",
                    "description": "Dostarlimab will be administered.",
                    "armGroupLabels": [
                        "Participants receiving GSK4381562 plus dostarlimab (Arm B)",
                        "Participants receiving GSK4381562 plus dostarlimab plus GSK4428859A (Arm C)",
                        "Participants receiving dostarlimab plus GSK4428859A (Arm D)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "GSK4428859A",
                    "description": "GSK4428859A will be administered.",
                    "armGroupLabels": [
                        "Participants receiving GSK4381562 plus dostarlimab plus GSK4428859A (Arm C)",
                        "Participants receiving dostarlimab plus GSK4428859A (Arm D)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Arms A, B, C: Number of participants with dose-limiting toxicities (DLTs)",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Arms A, B, C, D: Number of participants with adverse events (AEs) and serious adverse events (SAEs)",
                    "timeFrame": "Up to 27 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with clinically significant changes in laboratory parameters, electrocardiogram (ECG) and vital signs",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Number of participants with dose reductions or delays",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Number of participants with withdrawals due to AEs",
                    "description": "Number of participants with adverse events leading to permanent discontinuation of study treatment or withdrawal from study by overall frequency will be assessed.",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Overall response rate will be calculated as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. It is defined as the percentage of participants with a best overall confirmed complete response (CR) or partial response (PR) at any time as per disease-specific criteria.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Number of participants with positive antidrug antibodies (ADA) to GSK4381562",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Titers of ADA to GSK4381562",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Number of participants with positive ADA to dostarlimab",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Titers of ADA to dostarlimab",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Number of participants with positive ADA to GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Titers of ADA to GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Serum concentrations of GSK4381562",
                    "timeFrame": "Up to 4 months"
                },
                {
                    "measure": "Serum concentrations of dostarlimab",
                    "timeFrame": "Up to 4 months"
                },
                {
                    "measure": "Serum Concentrations of GSK4428859A",
                    "timeFrame": "Up to 4 months"
                },
                {
                    "measure": "Maximum observed plasma concentration (Cmax) of GSK4381562 monotherapy",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Cmax of GSK4381562 in combination with dostarlimab",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Cmax of GSK4381562 in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Cmax following administration of dostarlimab in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Minimum observed plasma concentration (Cmin) of GSK4381562 monotherapy",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Cmin of GSK4381562 in combination with dostarlimab",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Cmin of GSK4381562 in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Cmin following administration of dostarlimab in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "Area under the plasma concentration curve from time zero to last time of quantifiable concentration (AUC[0-t]) of GSK4381562",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "AUC(0-t) of GSK4381562 in combination with dostarlimab",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "AUC(0-t) of GSK4381562 in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "AUC(0-t) following administration of dostarlimab in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "AUC from time zero to infinity (AUC[0-infinity]) of single dosing of GSK4381562",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "AUC(0-infinity) of single dosing of GSK4381562 in combination with dostarlimab",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "AUC(0-infinity) of single dosing of GSK4381562 in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                },
                {
                    "measure": "AUC(0-infinity) following administration of dostarlimab in combination with GSK4428859A",
                    "timeFrame": "Up to 27 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria:\n\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:\n\n  * Is not a woman of childbearing potential (WOCBP) or\n  * Is a WOCBP and using a contraceptive method that is highly effective with a failure rate of less than (\\<)1 percent (\\[%\\] per year), during the intervention period and for specified time after end of study treatment.\n  * A WOCBP must have a negative highly sensitive pregnancy test within 24-48 hours before the first dose of study intervention.\n* Histological or cytological documentation of loco-regionally recurrent solid tumors where curative treatment options have been exhausted, or metastatic solid tumors; types as follows:\n\n  * head and neck squamous cell carcinoma (HNSCC)\n  * non-small-cell lung cancer (NSCLC)\n  * breast cancer (BC)\n  * clear cell renal cell cancer (ccRCC)\n  * gastric cancer (GC)\n  * colorectal cancer (CRC)\n  * endometrial cancer (EC)\n  * ovarian epithelial cancer (OEC)\n* Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists.\n\n  \u2022Measurable disease per RECIST 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\n* Life expectancy of at least 12 weeks.\n* Adequate organ function, as defined in the protocol.\n* For participants enrolled in a PK/PD cohort, participant agrees to a fresh tumor biopsy during Screening and at approximately 6-weeks after treatment initiation.\n\nExclusion Criteria:\n\n* Prior treatment with the following therapies (specified time periods are from last dose of prior treatment to first dose of GSK4381562):\n\n  * Any therapy directed against Polio virus receptor (PVR)-related immunoglobulin domain-containing (PVRIG) (COM701 or other anti-PVRIG monoclonal antibody \\[mAb\\]) or other cluster of differentiation (CD)226 axis receptor (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain \\[TIGIT\\] or CD96) at any time.\n  * Other prior immunotherapy, chemotherapy, targeted therapy, biological therapy or radiation therapy within specified periods as defined in the protocol.\n  * Investigational therapy: if the participant has participated in a clinical study and has received an investigational product within 4 weeks or 5 half-lives of the investigational product (whichever is shorter).\n* Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation.\n* Toxicity from previous anticancer treatment, including:\n\n  * Greater than or equal to Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or\n  * History of myocarditis of any grade during a previous treatment with immunotherapy\n  * Toxicity related to prior treatment that has not resolved to less than or equal to (\\<=)Grade 1. Non clinically relevant Grade 2 toxicities, not constituting a safety risk by investigator judgment are allowed.\n* Participant has a known additional malignancy that progressed or required active treatment within the last 2 years.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "877-379-3718",
                    "email": "GSKClinicalSupportHD@gsk.com"
                },
                {
                    "name": "EU GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "+44 (0) 20 89904466",
                    "email": "GSKClinicalSupportHD@gsk.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "GSK Clinical Trials",
                    "affiliation": "GlaxoSmithKline",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Pamela N. Munster",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Antoinette Tan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Debra L. Richardson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Anthony J Olszanski",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Reva Elaine Schneider",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Drew W Rasco",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Vaia Florou",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Samantha Bowyer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "John Hilton",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Lillian Siu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Shnghai",
                    "zip": "200126",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Ye Guo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ]
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Dijon",
                    "zip": "21000",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Francois Ghiringhelli",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.31667,
                        "lon": 5.01667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Lille",
                    "zip": "59000",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Loic Lebellec",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.63297,
                        "lon": 3.05858
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Chiba",
                    "zip": "277-8577",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Toshihiko Doi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.6,
                        "lon": 140.11667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Tokyo",
                    "zip": "104-0045",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Noboru Yamamoto",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.6895,
                        "lon": 139.69171
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Dong-Wan Kim",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Byoung Chul Cho",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Elena Garralda Cabanas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Victor Moreno Garcia",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Mar\u00eda Jos\u00e9 de Miguel Luken",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "M\u00e1laga",
                    "zip": "29010",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Javier Garc\u00eda Corbacho",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.72016,
                        "lon": -4.42034
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Natalie Cook",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Sutton",
                    "zip": "SM2 5PT",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Johann S De Bono",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.35,
                        "lon": -0.2
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "IPD for this study will be made available via the Clinical Study Data Request site.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.",
            "accessCriteria": "Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",
            "url": "http://clinicalstudydatarequest.com"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M5548",
                    "name": "Carcinoma, Renal Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4906",
                    "name": "Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T1341",
                    "name": "Clear Cell Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000719628",
                    "term": "Dostarlimab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M353292",
                    "name": "Dostarlimab",
                    "asFound": "Over time",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}